NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France | Biotech Hunter

Enrollment

99,999

Participants

Timeline

Start Date

September 8, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Tablets, 20mg once daily

DRUG

Vitamin K antagonists

Tablets, dose is based on International Normalized Ratio

DRUG

dabigatran (Pradaxa)

Tablets, 150 mg twice daily

Trial Locations (1)

Many Locations, Multiple Locations